BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Alkem Laboratories Ltd.’s stock price has recently corrected approximately 10% despite strong Q1 FY21 performance.
We believe the correction was mainly due to reported decline in secondary sales data for Q2 FY21 and dominance of acute portfolio (approximately 85% of India sales), which would take longer to recover.
In our view, this temporary situation caused by the lockdown has already been captured in the price.
There remains a probability of positive surprise considering the strong traction in trade generics and relative outperformance against the industry in top brands like Pan, Pan- D, etc.
We remain positive on the long-term outlook based on sustainable growth in the domestic market and continuous scale-up in U.S, generic business coupled with an improving margin profile.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR